Application of mesenchymal stem cells in treatment of digestive tract fistula

Abstract

The invention belongs to the technical field of biological medicine, and particularly relates to application of mesenchymal stem cells to treatment of digestive tract fistula. The present invention relates to a compound for the treatment of complex perianal fistula associated with non-active or mild-active Crohn's disease, which patients are insufficiently responsive to at least one existing drug treatment, for the treatment of complex perianal fistula in adult patients suffering from non-active / mild-active intracavity Crohn's disease.

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to an application of mesenchymal stem cells in treating digestive tract fistulas. Background Art

[0002] Crohn's disease is a chronic inflammatory disease of the digestive system. Patients may develop complex perianal fistulas, causing severe pain, bleeding, swelling, infection, and abnormal anal excretion. Despite advances in medical and surgical techniques, complex perianal fistulas remain challenging for clinicians. In a survey of 8 patients, patients with perianal fistulas felt more unhygienic and uncomfortable about their condition than Crohn's patients without perianal fistulas. Therefore, there is an urgent need to develop new means to deal with this thorny problem. Adipose-Derived Stem Cells (ADSCs) are a type of stem cell with multidirectional differentiation potential isolated from adipose tissue in recent years. Studies have shown that 2% of cells in adipose tissue are adipose stem cells, which is much higher than the proportion obtained from bone marrow (0.002%). The proliferation rate of in vitro culture is higher than that of bone marrow stem cells. Adipose stem cells do not express ligands for NK receptors and do not cause immune rejection reactions. Therefore, ADSCs show application prospects that other stem cells cannot achieve. Summary of the invention

[0003] In order to improve the efficacy of drugs and meet the medication needs of clinical patients, a mesenchymal stem cell application for the treatment of digestive tract fistulas is provided. It is used to treat complex perianal fistulas associated with inactive or mildly active Crohn's disease, in which patients have an insufficient response to at least one existing drug treatment, and is used to treat complex perianal fistulas in adult patients with inactive / mildly active intracavitary Crohn's disease.

[0004] To achieve the above object, the present invention provides the following technical solutions:

[0005] A use of mesenchymal stem cells for treating digestive tract fistula.

[0006] The mesenchymal stem cells are human allogeneic adipose-derived mesenchymal stem cells.

[0007] Compared with the prior art, the present invention has the following beneficial effects:

[0008] For the treatment of complex perianal fistulas associated with inactive or mildly active Crohn's disease who have had an inadequate response to at least one existing drug therapy. It exhibits immunomodulatory and local anti-inflammatory effects at the site of inflammation, providing a new treatment option for closing complex perianal fistulas caused by Crohn's disease.

[0009] Both autologous adipose-derived stem cell (ADSC) transplantation and allogeneic ADSC transplantation for the treatment of anal fistula have special advantages such as less trauma, no sphincter damage, mild pain, fast repair, low recurrence rate, and short hospitalization time. Their safety and effectiveness have been preliminarily certified. Their advantages are not available in current traditional treatments such as surgery and minimally invasive treatments. DETAILED DESCRIPTION

[0010] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0011] Example

[0012] A use of mesenchymal stem cells for treating digestive tract fistula.

[0013] The mesenchymal stem cells are human allogeneic adipose-derived mesenchymal stem cells.

[0014] The results of preclinical studies have shown that human allogeneic adipose-derived mesenchymal stem cells can inhibit the proliferation of lymphocytes, Th1 cells, and Th17 cells, inhibit the secretion of inflammatory factor TNF-α by activated immune cells, promote the proliferation of Treg lymphocytes and the expression of IDO, and through this immune regulation, reduce inflammatory responses and thus heal wounds.

[0015] Human allogeneic adipose-derived mesenchymal stem cells showed good therapeutic effects in a rat Crohn's disease model, and the pharmacodynamic effects among high, medium and low doses were dose-related.

[0016] Relevant human clinical studies have shown that adipose stem cell treatment of anal fistula has special advantages such as less trauma, no sphincter damage, mild pain, rapid repair, low recurrence rate and short hospitalization time.

[0017] Adipose-Derived Stem Cells (ADSC) are stem cells isolated from adipose tissue and have multidirectional differentiation potential.

[0018] Studies have shown that 2% of cells in adipose tissue are adipose stem cells, which is much higher than the proportion obtained from the bone marrow (0.002%). The proliferation rate in vitro is higher than that of bone marrow stem cells, and they do not express NK receptor ligands and will not cause immune rejection reactions. Therefore, ADSCs have shown application prospects that other stem cells cannot achieve.

Claims

1. A use of mesenchymal stem cells for treating digestive tract fistula.

2. The use of mesenchymal stem cells for treating digestive tract fistula according to claim 1, characterized in that The mesenchymal stem cells are human allogeneic adipose-derived mesenchymal stem cells.